JPH0516426B2 - - Google Patents

Info

Publication number
JPH0516426B2
JPH0516426B2 JP59127698A JP12769884A JPH0516426B2 JP H0516426 B2 JPH0516426 B2 JP H0516426B2 JP 59127698 A JP59127698 A JP 59127698A JP 12769884 A JP12769884 A JP 12769884A JP H0516426 B2 JPH0516426 B2 JP H0516426B2
Authority
JP
Japan
Prior art keywords
formula
compound
valeryloxy
hydroxy
hexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59127698A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6013777A (ja
Inventor
Hatsutoberii Hooru
Hokuri Eruritsuhi
Kutsuaa Erunsuto
Rengusufueruto Hansu
Kaaru Uaiberu Erunsuto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4255488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0516426(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPS6013777A publication Critical patent/JPS6013777A/ja
Publication of JPH0516426B2 publication Critical patent/JPH0516426B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP59127698A 1983-06-22 1984-06-22 新規化合物 Granted JPS6013777A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3415/83-4 1983-06-22
CH341583 1983-06-22

Publications (2)

Publication Number Publication Date
JPS6013777A JPS6013777A (ja) 1985-01-24
JPH0516426B2 true JPH0516426B2 (cg-RX-API-DMAC10.html) 1993-03-04

Family

ID=4255488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59127698A Granted JPS6013777A (ja) 1983-06-22 1984-06-22 新規化合物

Country Status (26)

Country Link
US (1) US4598089A (cg-RX-API-DMAC10.html)
EP (1) EP0129748B1 (cg-RX-API-DMAC10.html)
JP (1) JPS6013777A (cg-RX-API-DMAC10.html)
KR (1) KR920002314B1 (cg-RX-API-DMAC10.html)
AT (1) ATE30025T1 (cg-RX-API-DMAC10.html)
AU (1) AU572851B2 (cg-RX-API-DMAC10.html)
BG (1) BG60766B2 (cg-RX-API-DMAC10.html)
CA (1) CA1247547A (cg-RX-API-DMAC10.html)
DE (2) DE19875045I2 (cg-RX-API-DMAC10.html)
DK (1) DK160496C (cg-RX-API-DMAC10.html)
ES (1) ES8600650A1 (cg-RX-API-DMAC10.html)
FI (1) FI78694C (cg-RX-API-DMAC10.html)
GR (1) GR82120B (cg-RX-API-DMAC10.html)
HU (1) HU193579B (cg-RX-API-DMAC10.html)
IE (1) IE57761B1 (cg-RX-API-DMAC10.html)
IL (1) IL72122A (cg-RX-API-DMAC10.html)
LU (1) LU90302I2 (cg-RX-API-DMAC10.html)
LV (1) LV5747B4 (cg-RX-API-DMAC10.html)
MC (1) MC1602A1 (cg-RX-API-DMAC10.html)
MX (1) MX9203633A (cg-RX-API-DMAC10.html)
NL (1) NL980029I2 (cg-RX-API-DMAC10.html)
NO (2) NO159941C (cg-RX-API-DMAC10.html)
NZ (1) NZ208521A (cg-RX-API-DMAC10.html)
PH (1) PH19704A (cg-RX-API-DMAC10.html)
PT (1) PT78777B (cg-RX-API-DMAC10.html)
ZA (1) ZA844558B (cg-RX-API-DMAC10.html)

Families Citing this family (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
ZA859574B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Process for the manufacture of oxetanones
JPH0618793Y2 (ja) * 1986-06-13 1994-05-18 パイオニア株式会社 作業台
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
MY116591A (en) * 1996-04-26 2004-02-28 Hoffmann La Roche Process for the production of lipstatin and tetrahydrolipstatin
KR100479968B1 (ko) * 1997-02-05 2005-03-30 에프. 호프만-라 로슈 아게 위장 리파아제 억제제의 용도
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
RU2234917C2 (ru) * 1997-12-24 2004-08-27 Кнолль Акциенгезелльшафт Терапевтические средства
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
KR20010079635A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
KR20010079636A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
KR20010102965A (ko) 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및담즙산 격리제의 병용
JP2002533413A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびフィブリン酸誘導体の組み合わせ
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
KR20010099937A (ko) 1998-12-23 2001-11-09 윌리암스 로저 에이 심혈관 징후용 콜레스테릴 에스테르 전달 단백질 억제제및 피브르산 유도체의 조합물
EP1342475A1 (en) 1998-12-23 2003-09-10 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DE60000796T2 (de) * 1999-01-29 2003-09-18 F. Hoffmann-La Roche Ag, Basel Reinigung von Lipstatin
CA2379308A1 (en) * 1999-07-14 2001-01-25 Geltex Pharmaceuticals, Inc. Fat-binding polymers, optionally combined with lipase inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
EP1142572A1 (de) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Oxetanon-enthaltende Präparate zur Behandlung von Darmerkrankungen
MXPA02012583A (es) * 2000-06-27 2003-04-10 Hoffmann La Roche Metodo para preparacion de una composicion.
JP4265911B2 (ja) * 2000-07-28 2009-05-20 エフ．ホフマン−ラ ロシュ アーゲー 新規医薬組成物
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
DE60133470T2 (de) 2000-08-09 2009-05-07 F. Hoffmann-La Roche Ag Lipase inhibitoren zur behandlung von dyspepsia
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
US6610685B2 (en) 2000-12-27 2003-08-26 Hoffmann-La Roche Inc. Fused indole derivatives
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
AU2002338896B2 (en) * 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
HUP0401298A3 (en) 2001-08-30 2008-03-28 Alizyme Therapeutics Ltd Thieno [1,3] oxazin-4-ones with lipase inhibiting activity, process for their preparation and pharmaceutical compositions containing them
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
JP2005518347A (ja) 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
AU2002362061A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
EP1458882A2 (en) 2001-12-04 2004-09-22 Biogal Gyogyszergyar Rt. A fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
EA009368B1 (ru) 2001-12-20 2007-12-28 Оси Фармасьютикалз, Инк. Соединения-ингибиторы липазы поджелудочной железы, их синтез и применение
EP1465885A4 (en) 2002-01-17 2005-04-27 Pharmacia Corp NOVEL ALKYL / ARYL HYDROXY OR CETOTHIEPINE COMPOUNDS AS INHIBITORS OF BILIARY ACID TRANSPORT OF THE ILEAL TYPE AND ABSORPTION OF TAUROCHOLATE
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
CN100383124C (zh) * 2002-02-04 2008-04-23 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的喹啉衍生物
PL372463A1 (en) * 2002-02-28 2005-07-25 F.Hoffmann-La Roche Ag Thiazole derivatives as npy receptor antagonists
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
US7728153B2 (en) * 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
CN1325050C (zh) * 2002-04-26 2007-07-11 霍夫曼-拉罗奇有限公司 包含脂肪酶抑制剂和葡甘露聚糖的药物组合物
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN1665791A (zh) * 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
RU2324685C2 (ru) * 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
PL375878A1 (en) * 2002-09-12 2005-12-12 F.Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
BR0316556A (pt) * 2002-11-25 2005-10-04 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
WO2004113314A1 (en) * 2003-06-23 2004-12-29 Biocon Limited Novel boronate esters
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2003253254A1 (en) * 2003-07-17 2005-02-04 Biocon Limited Preparation of tetrahydrolipstatin by hydrogenation of lipstatin, solvent extraction and purification
DE602004019939D1 (de) * 2003-08-12 2009-04-23 Hoffmann La Roche Thiazolderivate als npy-antagonisten
KR20060037435A (ko) * 2003-08-12 2006-05-03 에프. 호프만-라 로슈 아게 2-아미노-5-벤조일싸이아졸 ｎｐｙ 길항물질
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
EP1669350B1 (en) 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2548671C (en) * 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
US20070191495A1 (en) * 2004-01-16 2007-08-16 Fuji Oil Company, Limited Lipase inhibitor
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
AU2005239788A1 (en) 2004-05-10 2005-11-17 University Of Copenhagen Flaxseeds for body weight management
EP1771162B1 (en) * 2004-07-19 2013-06-05 Xenia Pharma Capsaicin inhibitors for the treatment of obesity-related disorders
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CA2609634C (en) * 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP1945635B1 (en) * 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US7355055B2 (en) * 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CA2630270A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
BRPI0619268A2 (pt) * 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
RU2412182C2 (ru) * 2005-11-30 2011-02-20 Ф.Хоффманн-Ля Рош Аг Производные 1,1-диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистамина 3 (н3)
CA2631128A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
DE602006010738D1 (de) * 2005-12-15 2010-01-07 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
WO2007068641A1 (en) * 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo [2 , 3-b] pyridine derivatives as h3 receptor modulators
SK22006A3 (sk) * 2006-01-03 2007-08-02 Biotika, A. S. Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
ES2349160T3 (es) * 2006-01-23 2010-12-28 F. Hoffmann-La Roche Ag Derivados de la ciclohexil sulfonamida con actividad frente a los receptores h3.
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2008014532A (es) * 2006-05-30 2008-11-27 Hoffmann La Roche Derivados de piperidinil pirimidinas.
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
CA2687964A1 (en) * 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2008149321A2 (en) * 2007-06-06 2008-12-11 Ranbaxy Laboratories Limited Process for the preparation of orlistat
US9066536B2 (en) 2007-09-12 2015-06-30 University Of Copenhagen Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20100196464A1 (en) * 2007-09-17 2010-08-05 Dr. Reddy's Laboratories Limited Orlistat pharmaceutical formulations
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
EP2280766A1 (en) 2007-12-11 2011-02-09 CytoPathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
ES2755736T3 (es) * 2008-03-26 2020-04-23 Biocon Ltd Proceso de fermentación mejorado para un coeficiente de rendimiento más alto de inhibidor de lipasa respecto al ácido graso consumido
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2141236A1 (en) 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Process for production of lipstatin and microorganisms therefore
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2347660A4 (en) 2008-10-03 2014-06-11 Sigma Alimentos Sa De Cv COMPOSITION FOR PROMOTING THE CONTROL OF TOTAL AND LDL CHOLESTERIN AND / OR WEIGHT REDUCTION AND / OR THERMOGENESIS
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010043592A1 (en) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
RU2412713C2 (ru) * 2009-05-14 2011-02-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Фармацевтическая композиция, биологически активная добавка и способ уменьшения поглощения жира из пищи
EP2473515A4 (en) 2009-09-04 2013-11-27 Univ Toledo PROCESS FOR PREPARING OPTICALLY PURE BETA LACTONS FROM ALDEHYDE AND COMPOSITIONS MADE THEREOF
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
US8524909B2 (en) 2010-02-02 2013-09-03 Hoffmann-La Roche Inc. Tetrahydro-pyran derivatives
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
ES2662710T3 (es) 2010-05-24 2018-04-09 Swedish Oat Fiber Ab Dispersión acuosa que comprende galactolípidos y método de producción de la misma
EP2392327A1 (en) 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Use of orlistat for the anti-parasitic treatment of a parasitic disease
WO2012004588A2 (en) 2010-07-06 2012-01-12 Astrazeneca Ab Therapeutic agents 976
CN101885713B (zh) * 2010-07-19 2011-11-30 大邦(湖南)生物制药有限公司 一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN101948450B (zh) * 2010-10-13 2013-04-24 鲁南制药集团股份有限公司 一种生产制备奥利司他的方法
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
BR112013010157B1 (pt) 2010-11-04 2020-02-04 Albireo Ab iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
CN102304105B (zh) * 2011-07-15 2013-07-10 鲁南新时代生物技术有限公司 一种制备高纯度奥利司他的方法
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN103030613B (zh) * 2011-09-29 2014-11-12 北大方正集团有限公司 一种利普司他汀的提纯方法
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014060445A1 (en) 2012-10-19 2014-04-24 Akzo Nobel Chemicals International B.V. Method for preparing high purity orlistat
CN102936234B (zh) * 2012-11-15 2015-04-01 江苏阿尔法药业有限公司 一种制备脂肪酶抑制剂奥利司他的方法
CN102993134B (zh) * 2012-12-31 2015-08-05 鲁南新时代生物技术有限公司 一种利普司他汀的提纯方法
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN113121450A (zh) 2014-08-29 2021-07-16 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
IL283182B2 (en) 2018-11-20 2025-10-01 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
MA54261B1 (fr) 2019-01-18 2025-03-28 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
JP7722195B2 (ja) 2020-02-05 2025-08-13 日油株式会社 膵液瘻の予防または治療剤
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones

Also Published As

Publication number Publication date
AU2947884A (en) 1985-01-03
MX9203633A (es) 1992-07-01
GR82120B (cg-RX-API-DMAC10.html) 1984-12-13
NL980029I2 (nl) 1999-06-01
DK160496C (da) 1991-08-26
PT78777A (en) 1984-07-01
NL980029I1 (nl) 1999-01-04
US4598089A (en) 1986-07-01
IL72122A0 (en) 1984-10-31
EP0129748B1 (de) 1987-09-30
CA1247547A (en) 1988-12-28
KR850000530A (ko) 1985-02-27
BG60766B2 (bg) 1996-02-29
HUT34545A (en) 1985-03-28
NO842512L (no) 1984-12-27
IE841566L (en) 1984-12-22
EP0129748A1 (de) 1985-01-02
PH19704A (en) 1986-06-16
FI78694B (fi) 1989-05-31
HU193579B (en) 1987-10-28
ATE30025T1 (de) 1987-10-15
KR920002314B1 (ko) 1992-03-21
MC1602A1 (fr) 1985-05-09
DK308584D0 (da) 1984-06-22
LV5747B4 (lv) 1996-12-20
FI78694C (fi) 1989-09-11
NO159941B (no) 1988-11-14
ES533557A0 (es) 1985-10-16
ZA844558B (en) 1985-02-27
NZ208521A (en) 1988-02-29
DE3466538D1 (de) 1987-11-05
LV5747A4 (lv) 1996-10-20
AU572851B2 (en) 1988-05-19
PT78777B (en) 1986-09-15
DK160496B (da) 1991-03-18
ES8600650A1 (es) 1985-10-16
IL72122A (en) 1987-07-31
IE57761B1 (en) 1993-03-24
FI842422L (fi) 1984-12-23
JPS6013777A (ja) 1985-01-24
NO2000003I1 (no) 2000-05-31
NO159941C (no) 1989-02-22
DE19875045I2 (de) 2000-01-20
DK308584A (da) 1984-12-23
LU90302I2 (fr) 1998-12-21
FI842422A0 (fi) 1984-06-14

Similar Documents

Publication Publication Date Title
JPH0516426B2 (cg-RX-API-DMAC10.html)
FI87803C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla tricykliska foereningar
CA1160972A (en) Polyether compounds
CA1153966A (en) Physiologically active substance, ebelactone and production thereof
JPS5878598A (ja) 抗生物質ＬＬ―Ｃ２３０２４βおよびイオタを生産することが可能な微生物
LU85953A1 (fr) Compose antibiotique antitumoral
EP0246975A1 (fr) Nouvelles substances immuno-suppressives, leur préparation par culture de streptomyces sp. (CBS 162.86) et les compositions pharmaceutiques qui les contiennent
EP0009636B1 (en) 3-chloro-6-hydroxy-5-methylbenzoic acid derivatives, corresponding pharmaceutical preparations, growth promoting compositions, the use of the compounds for promoting growth in certain animals and their manufacture
PL130950B1 (en) Process for preparing novel metabolite streptomyces,m. 139603,and agent for use in stock-breeding of ruminants
MC1615A1 (fr) Antibiotiques
JPH0447648B2 (cg-RX-API-DMAC10.html)
CN1045997C (zh) 抗球虫剂组合物及其制备方法
KR790000957B1 (ko) 항생물질 a-28086의 제조방법
JP3010215B1 (ja) リパ―ゼ阻害剤
JPH0631283B2 (ja) 生理活性物質ｆａ−１８１９，その製造法およびそれを含有する治療剤
FR2515207A1 (fr) Agents antibacteriens ll-c23024 b et iota, leur procede de preparation et microorganisme actinomadura yumaense nrrl 12515
JPH0479354B2 (cg-RX-API-DMAC10.html)
JPS6311341B2 (cg-RX-API-DMAC10.html)
IE47098B1 (en) Bl580 zeta
EP0451273A1 (en) Polyether antibiotic mi215-nf3, production thereof, and drug for treating fowl coccidiosis
MC1301A1 (fr) Derives d'urethane
JPH0747599B2 (ja) 新規酸性多環式エーテル抗生物質およびその製造に有用な微生物
JPH05221867A (ja) Ｉｌ−６誘導剤
JPH09202797A (ja) ５α−還元酵素阻害化合物ｄ１０６７３３１
BE891734A (fr) Antibiotiques macrolides, leur procede de preparation et microorganismes s'y rapportant, leurs produits intermediaires et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term